Hsu YC, Yeh ML, Wong GLH, et al. - This study was carried out to evaluate the Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic hepatitis B. Researchers conducted an international multicenter cohort study including treatment-naïve chronic hepatitis B (CHB) patients who initiated on entecavir (ETV) or tenofovir disoproxil fumarate (TDF) without baseline malignancy. The incidences were calculated and the baseline determinants of HBsAg seroclearance were explored using competing risk regression. A total of 4,769 patients were included in this study (median age, 50 years; 69.05% male), with a median follow-up of 5.16 years (26,614.47 person-years). The findings illustrate that HBsAg seroclearance rarely occurs in CHB patients treated with ETV or TDF and is correlated with low-level viremia, alanine aminotransferase flare, bilirubin level, and fatty liver.